Sanofi’s Zimulti NDA Resubmission Could Be Late 2008, At Earliest

Sanofi-Aventis will likely not be able to resubmit the NDA for its obesity drug Zimulti (rimonabant) until the end of 2008, at the earliest, when data becomes available from its ongoing study of the drug in diabetes patients